Biodexa Pharmaceuticals Plc — Form F-1/A

On July 1–July 29, 2026, Biodexa Pharmaceuticals completed three concurrent offerings: (1) registered direct offering of 82,809 depositary shares (4.14M ordinary shares) and 200,143 pre-funded warrants at $2.85/share, raising ~$0.8M gross; (2) private placement of Series M warrants (282,952 exercisable for depositary shares) and pre-funded warrants (350,877 depositary shares) at ~$2.85/share, raising ~$1.8M gross; (3) warrant inducement where holders exercised 609,756 depositary shares in Series L warrants at reduced $2.85 price, receiving Series O warrants (1,219,512 exercisable), raising ~$1.7M gross. As of July 30, 2026, ~127.8M ordinary shares (2.56M depositary shares) were registered for resale, comprised of pre-funded warrant shares (17.5M), Series M warrant shares (14.1M), Series N warrant shares (35.1M), and Series O warrant shares (61.0M). Total aggregate gross proceeds approximately $3.6M (before expenses).